Scientists in Switzerland have developed a peptide that binds to the protein calprotectin, a marker of major inflammatory disorders, and shown that it is suitable for diagnostic tests. The use of synthetic peptides for sensing disease markers is of great interest as they are more precise, robust, and cheaper than antibodies commonly used in diagnostic tests.
Immunic (IMUX) Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting
/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential 17.11.2022 / 12:30 CET/CEST The issuer is solely responsible for th.